EMA tries 'new approach' to aid gene therapy development
This article was originally published in SRA
Executive Summary
Developers of gene therapies tend not to be familiar with the regulatory environment and so the European Medicines Agency is trying a new approach aimed at addressing their needs in a new draft guideline aimed at supporting and facilitating the development of such products1,2.